|Bid||0.0000 x 1100|
|Ask||0.0000 x 1000|
|Day's Range||3.9600 - 4.2738|
|52 Week Range||1.8200 - 6.7200|
|Beta (5Y Monthly)||2.53|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 31, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.25|
Good morning, and thank you all for joining GlycoMimetics Corporate Update Conference Call. The webcast replay will also be available in the Investor Relations section of the Company's website for 30 days. Joining me on the call today from GlycoMimetics are Rachel King, Chief Executive Officer; Brian Hahn, Senior VP and Chief Financial Officer; and Dr. Helen Thackray; our Senior VP of Clinical Development and Chief Medical Officer.
GlycoMimetics, Inc. (Nasdaq: GLYC) today reported its financial results for the second quarter ended June 30, 2020, and highlighted recent company events. Cash and cash equivalents at June 30, 2020 were $149.8 million.
GlycoMimetics, Inc. (Nasdaq: GLYC) announced today that it will host a conference call and webcast to report its second quarter financial results on Friday, July 31, 2020, at 8:30 a.m. ET.